atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
August 06 2021 - 6:10PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced that it will participate
in a fireside chat and one-on-one investor meetings at the
Canaccord Genuity Growth Conference, to be held virtually from
August 10-12, 2021.
Presentation details can be found below:
41st Annual Canaccord
Genuity Growth ConferenceFormat: Fireside chat Date and
Time: Tuesday, August 10th, 2:30 p.m. ETWebcast link:
https://wsw.com/webcast/canaccord60/atai/2419868
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape. atai is dedicated to
acquiring, incubating and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders. atai's business model combines funding,
technology, scientific and regulatory expertise with a focus on
psychedelic therapy and other drugs with differentiated safety
profiles and therapeutic potential. By pooling resources and best
practices, atai aims to responsibly accelerate the development of
new medicines across its companies, seeking to effectively treat
and ultimately heal mental health disorders. atai's mission is to
bridge the gap between what the mental healthcare system currently
provides and what patients need. atai is headquartered in Berlin,
with offices in New York and London. For more information, please
visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. Forward-looking statements are
neither promises nor guarantees, but involve known and unknown
risks and uncertainties that could cause actual results to differ
materially from those projected, including, without limitation, the
important factors discussed under the caption “Risk Factors” in
atai's prospectus pursuant to Rule 424(b) filed with the U.S.
Securities and Exchange Commission (“SEC”) on June 21, 2021, as
such factors may be updated from time to time in atai's other
filings with the SEC. atai disclaims any obligation or undertaking
to update or revise any forward-looking statements contained in
this press release, other than to the extent required by applicable
law.
Investor Contact:Greg Weaveratai – Chief
Financial OfficerEmail: greg.weaver@atai.life
Media Contact:Anne DonohoeKCSA Strategic
CommunicationsPhone: +1 (212) 896-1265Email: atai@KCSA.com
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024